Radialis

Radialis Inc. is a medical technology company focused on advancing molecular imaging through its organ-targeted positron emission tomography (PET) systems. The company was incorporated in February 2016 as a spin-off from Lakehead University and the Thunder Bay Regional Health Research Institute. Its foundation is built upon the research of Dr. Alla Reznik, the company's Chief Scientific Officer, who identified the need for a better breast imaging alternative to mammography, which has limitations in detecting cancer in dense breast tissue. Dr. Reznik's work, which began around 2005, aimed to overcome the high radiation doses typically associated with PET scans, making it a safer option for screening.

The company's core product is the Radialis PET Imager, a compact and versatile imaging system designed for close-range, organ-specific scans of areas like the breast, head, and neck. Unlike conventional whole-body PET scanners, the Radialis system uses two adjustable planar detectors that can be positioned close to the area of interest, maximizing image resolution and sensitivity. This design allows it to resolve objects as small as 1.3mm and collect significantly more imaging data, revealing clinical details that might be missed by traditional systems. A key benefit of this heightened sensitivity is the ability to use lower doses of radioactive tracers, which reduces radiation exposure for the patient. The system is portable and can be integrated into existing nuclear medicine facilities to complement traditional PET/CT machines.

Radialis operates in the medical device manufacturing market, serving healthcare providers and clinical research facilities. Its business model revolves around the sale of the Radialis PET Imager. The company has achieved significant regulatory milestones, receiving FDA clearance for marketing in the United States in July 2022 and Health Canada clearance in June 2025. These approvals permit the imager to be used for measuring the distribution of injected positron-emitting radiopharmaceuticals to determine various metabolic and physiologic functions. The company has secured financing from investors including Archangel Networks' Axion Fund to support its commercial launch and growth. Headquartered in Thunder Bay, Ontario, Radialis maintains advanced manufacturing operations in the city, leveraging local resources and collaborations.

Keywords: organ-targeted PET, positron emission tomography, medical imaging, molecular imaging, cancer detection, breast cancer imaging, diagnostic equipment, low-dose imaging, high-resolution imaging, Positron Emission Mammography, PEM, nuclear medicine, radiopharmaceuticals, medical device, oncology imaging, neurology imaging, cardiology imaging, clinical trials, FDA clearance, Health Canada clearance